@article{b9424b477c8f4c959790ec515f735a09,
title = "BET bromodomain inhibition blocks the function of a critical AR-independent master regulator network in lethal prostate cancer",
abstract = "BET bromodomain inhibitors block prostate cancer cell growth at least in part through c-Myc and androgen receptor (AR) suppression. However, little is known about other transcriptional regulators whose suppression contributes to BET bromodomain inhibitor anti-tumor activity. Moreover, the anti-tumor activity of BET bromodomain inhibition in AR-independent castration-resistant prostate cancers (CRPC), whose frequency is increasing, is also unknown. Herein, we demonstrate that BET bromodomain inhibition blocks growth of a diverse set of CRPC cell models, including those that are AR-independent or in which c-Myc is not suppressed. To identify transcriptional regulators whose suppression accounts for these effects, we treated multiple CRPC cell lines with the BET bromodomain inhibitor JQ1 and then performed RNA-sequencing followed by Master Regulator computational analysis. This approach identified several previously unappreciated transcriptional regulators that are highly expressed in CRPC and whose suppression, via both transcriptional or post-translational mechanisms, contributes to the anti-tumor activity of BET bromodomain inhibitors.",
author = "Coleman, {Daniel J.} and Lina Gao and King, {Carly J.} and Jacob Schwartzman and Joshua Urrutia and Archana Sehrawat and Junior Tayou and Ariel Balter and Julja Burchard and Chiotti, {Kami E.} and Derrick, {Daniel S.} and Duanchen Sun and Zheng Xia and Heiser, {Laura M.} and Alumkal, {Joshi J.}",
note = "Funding Information: Acknowledgements This research was supported by: National Institutes of Health (NIH)/National Cancer Institute (NCI) R01 award CA178610; the Pacific Northwest Prostate Cancer SPORE/NCI (P50 CA097186); Cancer Center Support Grant (CCSG) (P30 CA069533); the Oregon Clinical and Translational Research Institute (OCTRI) (UL1TR000128) from the National Center for Advancing Translational Sciences (NCATS), a component of the NIH; Department of Defense Synergistic Idea Award (W81XWH-13-1-0420); Department of Defense Impact Awards (W81XWH-16-1-0597 and W81XWH-16-1-1601). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or DOD. Other support includes: Wayne D. Kuni and Joan E. Kuni Foundation, Prospect Creek Foundation, a Hope Foundation Award, and a Stand Up to Cancer—Prostate Cancer Foundation—Prostate Dream Team Translational Cancer Research Grant (SU2C-AACR-DT0409); this research grant is made possible by the generous support of the Movember Foundation. Stand Up To Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research (7465sc). We thank Dr. James Bradner at Dana-Farber Cancer Institute for providing the JQ1 compound used in in vivo studies. Funding Information: Conflict of interest JJA has performed consulting or held an advisory role with Astellas Pharma, Bayer, and Janssen Biotech, Inc. OHSU has received institutional research funding from Aragon Pharmaceuticals Inc., Astellas Pharma, Norvartis, Zenith Epigenetics Ltd, and Gilead Sciences Inc. These interests had no role in the design or conduct of this study. The remaining authors declare that they have no conflict of interest. Publisher Copyright: {\textcopyright} 2019, Springer Nature Limited.",
year = "2019",
month = jul,
day = "11",
doi = "10.1038/s41388-019-0815-5",
language = "English (US)",
volume = "38",
pages = "5658--5669",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "28",
}